Transdermal rotigotine improves sleep fragmentation in parkinson’s disease: results of the multicenter, prospective SLEEP-FRAM study
Kulisevsky, Jaime J.
MetadataShow full item record
Sleep disturbances occur frequently in patients with Parkinson’s disease (PD). The aim of this study was to investigate the effects of rotigotine on sleep fluctuations in a sample of PD patients with self-reported complaints of nocturnal awakenings. This prospective, open-label, observational, and multicenter study enrolled consecutive outpatients with PD and administered rotigotine (mean dose 8.9 mg/day) for 3 months. The primary endpoint was the change from baseline in sleep fragmentation, assessed using the sleep maintenance subscale score of the Parkinson’s Disease Sleep Scale (PDSS). The newly designed Parkinson’s Disease Sleep Fragmentation Questionnaire (PD-SFQ) was used to measure other sleep parameters. A total of 62 patients were enrolled (mean age 70.2 years; 66% male). At 3 months, rotigotine significantly improved sleep fragmentation from baseline on the PDSS-2 sleep maintenance subscale (from 3.4 ± 0.9 to 1.9 ± 1.4; 𝑃 < 0.0001). Rotigotine also significantly improved nocturnal motor symptoms (𝑃 < 0.0001), restless legs-like symptoms (𝑃 < 0.005), and nocturia (𝑃 = 0.004). Rotigotine significantly improved self-reported complaints of sleep fragmentation in PD patients and could be a useful treatment to improve this specific sleep problem in PD. However, these results are based on a small and clinically heterogeneous sample so they must be taken cautiously.
Is part ofParkinson’s Disease, 2015, vol. 2015, id. 131508
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by, (c) Pagonabarraga et al., 2015
Showing items related by title, author, creator and subject.
Alzheimer’s disease mutant mice exhibit reduced brain tissue stiffness compared to wild-type mice in both normoxia and following intermittent hypoxia mimicking sleep apnea Menal Castellote, Maria José; Jorba, Ignasi; Torres, Marta; Montserrat i Capdevila, Josep; Gozal, David; Colell, Anna; Piñol Ripoll, Gerard; Navajas, Daniel; Almendros, Isaac; Farré, Ramon (Frontiers Media, 2018)Background: Evidence from patients and animal models suggests that obstructive sleep apnea (OSA) may increase the risk of Alzheimer’s disease (AD) and that AD is associated with reduced brain tissue stiffness. Aim: To ...
Study of community-living Alzheimer’s patients’ adherence to the Mediterranean diet and risks of malnutrition at different disease stages Rocaspana-Garcia, Mariona; Blanco Blanco, Joan; Arias-Pastor, Alfonso; Gea Sánchez, Montserrat; Piñol Ripoll, Gerard (PeerJ, 2018)Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized by deficits in episodic memory. It is the most common form of dementia and affects 50–70% of patients with cognitive impairments over the age ...
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors Landa, Iñigo; Ruiz-Llorente, Sergio; Montero-Conde, Cristina; Inglada-Pérez, Lucía; Schiavi, Francesca; Leskelä, Susanna; Pita, Guillermo; Milne, Roger; Maravall Royo, Javier; Ramos, Ignacio; Andía, Víctor; Rodríguez-Poyo, Paloma; Jara-Albarrán, Antonino; Meoro, Amparo; Peso, Cristina del; Arribas, Luis; Iglesias, Pedro; Caballero, Javier; Serrano, Joaquín; Picó, Antonio; Pomares, Francisco; Giménez, Gabriel; López-Mondéjar, Pedro; Castello, Roberto; Merante-Boschin, Isabella; Pelizzo, Maria-Rosa; Mauricio Puente, Dídac; Opocher, Giuseppe; Rodríguez-Antona, Cristina; González- Neira, Anna; Matias-Guiu, Xavier; Santisteban, Pilar; Robledo, Mercedes (Public Library of Science, 2009)In order to identify genetic factors related to thyroid cancer susceptibility, we adopted a candidate gene approach. We studied tag- and putative functional SNPs in genes involved in thyroid cell differentiation and ...